Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Editas Medicine Inc EDIT

Healthcare Biotechnology
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9... see more

Recent & Breaking News (NDAQ:EDIT)

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

GlobeNewswire January 8, 2024

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

GlobeNewswire December 13, 2023

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

GlobeNewswire December 11, 2023

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

GlobeNewswire November 3, 2023

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

GlobeNewswire November 2, 2023

Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events

GlobeNewswire October 27, 2023

Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

GlobeNewswire October 16, 2023

Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer

GlobeNewswire September 25, 2023

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

GlobeNewswire September 25, 2023

Editas Medicine Announces Upcoming Investor Events

GlobeNewswire August 30, 2023

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

GlobeNewswire August 28, 2023

Editas Medicine Announces Second Quarter 2023 Results and Business Updates

GlobeNewswire August 2, 2023

Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization

GlobeNewswire July 27, 2023

Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update

GlobeNewswire July 26, 2023

Editas Medicine Reports Inducement Grant to New Chief Scientific Officer

GlobeNewswire July 25, 2023

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer

GlobeNewswire July 24, 2023

Editas Medicine Announces Pricing of Offering of Common Stock

GlobeNewswire June 14, 2023

Editas Medicine Announces Offering of Common Stock

GlobeNewswire June 14, 2023

Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial

GlobeNewswire June 9, 2023